Jörg Hausleiter

Interventional cardiologist / Cardiologist
Klinikum der Universität München - München, Germany

Latest contributions

Mitral abstracts session

22 May 2025 – From EuroPCR 2025

Examine critical mitral valve research through a series of abstracts focusing on mitral TEER outcomes. Topics include the impact of mitral valve complexity, prognostic significance of right atrial pressure, comparative analysis of degenerative versus functional mitral regurgitation, and validation of risk scores, providing valuable insights for...

Mitral abstracts session

Combined LAA closure and transcatheter mitral valve repair - LIVE Case

22 May 2025 – From EuroPCR 2025

An 82-year-old male patient with a history of PM (pacemaker) implantation in 2024, and ischaemic cardiomyopathy presented with symptomatic heart failure due to severe secondary mitral regurgitation and impaired LV function (EF 40 %). He also presented with recurrent gastro-intestinal bleeding while on DOAC for atrial...

Combined LAA closure and transcatheter mitral valve repair - LIVE Case

How to select appropriate cardiovascular intervention for a patient with tricuspid regurgitation?

21 May 2025 – From EuroPCR 2025

Learn how to select appropriate cardiovascular interventions for tricuspid regurgitation patients by considering comorbidities, anatomical factors influencing procedural success, and imaging criteria for device selection. The session includes patient vignettes to illustrate decision-making pathways.

How to select appropriate cardiovascular intervention for a patient with tricuspid regurgitation?

Mitral and tricuspid hotline: long-term outcomes

20 May 2025 – From EuroPCR 2025

Review long-term outcomes of transcatheter edge-to-edge repair (TEER) for mitral and tricuspid valve disease in this session. Highlights include pivotal trial results, mortality risk prediction tools, management of procedural failures, and real-world data, providing comprehensive insights into patient prognosis and therapeutic impact.

Mitral and tricuspid hotline: long-term outcomes

How to deal with secondary mitral regurgitation in 2025?

20 May 2025 – From EuroPCR 2025

Delve into the evolving management of secondary mitral regurgitation, and the critical role of the Heart Team. This session replay presents the latest clinical trials, treatment guidelines, and a case-based discussion covering medical and interventional strategies, heart failure optimization, frailty assessment, and advanced imaging techniques.

How to deal with secondary mitral regurgitation in 2025?

Pioneering innovation in the treatment of mitral and tricuspid regurgitation

20 May 2025 – From EuroPCR 2025

This interventional session explores therapeutic strategies for mitral and tricuspid regurgitation, focusing on the clinical decision-making process between repair and replacement. Through two clinical cases, a 78-year-old male patient with severe degenerative mitral regurgitation and an 88-year-old female patient with atrial functional mitral regurgitation, experts review available...

Pioneering innovation in the treatment of mitral and tricuspid regurgitation